RU2280443C2 - Новое применение для лечения заболеваний гастроэзофагеальной рефлюксной болезни - Google Patents

Новое применение для лечения заболеваний гастроэзофагеальной рефлюксной болезни Download PDF

Info

Publication number
RU2280443C2
RU2280443C2 RU2004114843/15A RU2004114843A RU2280443C2 RU 2280443 C2 RU2280443 C2 RU 2280443C2 RU 2004114843/15 A RU2004114843/15 A RU 2004114843/15A RU 2004114843 A RU2004114843 A RU 2004114843A RU 2280443 C2 RU2280443 C2 RU 2280443C2
Authority
RU
Russia
Prior art keywords
cannabinoid receptor
receptor agonist
cannabinoid
use according
medicament
Prior art date
Application number
RU2004114843/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2004114843A (ru
Inventor
Андерс ЛЕМАНН (SE)
Андерс ЛЕМАНН
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU2004114843A publication Critical patent/RU2004114843A/ru
Application granted granted Critical
Publication of RU2280443C2 publication Critical patent/RU2280443C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2004114843/15A 2001-11-23 2002-11-20 Новое применение для лечения заболеваний гастроэзофагеальной рефлюксной болезни RU2280443C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103936 2001-11-23
SE0103936-1 2001-11-23

Publications (2)

Publication Number Publication Date
RU2004114843A RU2004114843A (ru) 2005-05-27
RU2280443C2 true RU2280443C2 (ru) 2006-07-27

Family

ID=20286096

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004114843/15A RU2280443C2 (ru) 2001-11-23 2002-11-20 Новое применение для лечения заболеваний гастроэзофагеальной рефлюксной болезни

Country Status (20)

Country Link
US (1) US7358245B2 (enExample)
EP (1) EP1453497A1 (enExample)
JP (1) JP2005511632A (enExample)
KR (1) KR20050044582A (enExample)
CN (1) CN1610542A (enExample)
AR (1) AR037299A1 (enExample)
AU (1) AU2002353700A1 (enExample)
BR (1) BR0214319A (enExample)
CA (1) CA2466916A1 (enExample)
HU (1) HUP0402080A3 (enExample)
IL (1) IL161748A0 (enExample)
IS (1) IS7272A (enExample)
MX (1) MXPA04004774A (enExample)
NO (1) NO20042613L (enExample)
NZ (1) NZ532844A (enExample)
PL (1) PL369402A1 (enExample)
RU (1) RU2280443C2 (enExample)
TW (1) TW200407110A (enExample)
WO (1) WO2003043619A1 (enExample)
ZA (1) ZA200403785B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007513872A (ja) * 2003-10-24 2007-05-31 ゾルファイ　ファーマスーティカルズ　ゲゼルシャフト　ミット　ベシュレンクテル　ハフツング Ｃｂ１拮抗作用を示す化合物の新規の医学的用途および前記化合物を伴う組み合わせ治療
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
SE0303490D0 (sv) * 2003-12-19 2003-12-19 Astrazeneca Ab New use V
CA2585175A1 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
CA2589993C (en) * 2004-12-09 2012-07-03 Insys Therapeutics, Inc. Room-temperature stable dronabinol formulations
CN101516333A (zh) * 2006-08-04 2009-08-26 英西斯治疗学股份有限公司 水性屈大麻酚制剂
WO2009020666A1 (en) * 2007-08-06 2009-02-12 Insys Therapeutics Inc. Oral cannabinoid liquid formulations and methods of treatment
CN101998855A (zh) 2007-10-02 2011-03-30 戴维·布兰斯基 用于增强婴儿生长和发育的内源性大麻素
US20090208588A1 (en) * 2008-02-19 2009-08-20 Roger Wayne Brown GERD carbohydrate compositions
CN103588672A (zh) * 2013-10-28 2014-02-19 史克勇 一种治疗癌性疼痛的药物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939429A (en) * 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
US6017919A (en) * 1996-02-06 2000-01-25 Japan Tobacco Inc. Compounds and pharmaceutical use thereof
WO2001024645A1 (en) * 1999-10-07 2001-04-12 Societe Des Produits Nestle S.A. Nutritional composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
WO1999057106A1 (en) 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
US6348498B1 (en) 1998-05-29 2002-02-19 Neurosciences Research Foundation, Inc. Control of pain with endogenous cannabinoids
IL132661A (en) * 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for peripheral cannabinoid receptors
SE9904507D0 (sv) 1999-12-09 1999-12-09 Astra Ab New compounds
ATE368659T1 (de) 2000-06-15 2007-08-15 Schering Corp Thrombinrezeptorantagonisten
AUPR118000A0 (en) * 2000-11-02 2000-11-23 Amrad Operations Pty. Limited Therapeutic molecules and methods
FR2816938B1 (fr) * 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
US20020077322A1 (en) 2000-12-15 2002-06-20 Ayoub George S. Protection of neurons against glutamate-induced damage in glaucoma and other conditions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017919A (en) * 1996-02-06 2000-01-25 Japan Tobacco Inc. Compounds and pharmaceutical use thereof
US5939429A (en) * 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
WO2001024645A1 (en) * 1999-10-07 2001-04-12 Societe Des Produits Nestle S.A. Nutritional composition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Bueb J. L. et al. Receptor-independent effects of natural cannabinoids in rat peritoneal mast cells in vitro. Biochim. Biophys. Acta. 2001 Apr 23; 1538 (2-3):252-9. Реферат Entrez PubMed [on-line] PMID: 11336796 [найдено 26.09.2005]. *
Руководство по медицине «THE MERCK MANUAL». - М.: Мир, 1997, т.1, с.524-525. *

Also Published As

Publication number Publication date
RU2004114843A (ru) 2005-05-27
ZA200403785B (en) 2005-05-19
HUP0402080A2 (hu) 2005-02-28
WO2003043619A1 (en) 2003-05-30
KR20050044582A (ko) 2005-05-12
BR0214319A (pt) 2004-11-03
PL369402A1 (pl) 2005-04-18
EP1453497A1 (en) 2004-09-08
US20040266861A1 (en) 2004-12-30
NZ532844A (en) 2005-12-23
HUP0402080A3 (en) 2008-03-28
MXPA04004774A (es) 2004-07-30
AR037299A1 (es) 2004-11-03
WO2003043619A8 (en) 2005-03-17
IL161748A0 (en) 2005-11-20
TW200407110A (en) 2004-05-16
CN1610542A (zh) 2005-04-27
US7358245B2 (en) 2008-04-15
CA2466916A1 (en) 2003-05-30
NO20042613L (no) 2004-08-13
JP2005511632A (ja) 2005-04-28
AU2002353700A1 (en) 2003-06-10
IS7272A (is) 2004-05-19

Similar Documents

Publication Publication Date Title
US5393772A (en) Use of, and method of treatment using, hydroxycarbazole compounds for inhibition of smooth muscle migration and proliferation
US20020077328A1 (en) Selective cyclooxygenase-2 inhibitors and vasomodulator compounds for generalized pain and headache pain
JP2010532781A (ja) カンナビジオールおよびテトラヒドロカンナビジバリンを含む新規医薬製剤
RU2324484C2 (ru) Антагонисты метаботропного глутаматного рецептора 5 (mglur5) и способ для профилактики и лечения гастроэзофагеальной рефлюксной болезни (варианты)
US20070166336A1 (en) Stable and palatable oral liquid sumatriptan compositions
RU2280443C2 (ru) Новое применение для лечения заболеваний гастроэзофагеальной рефлюксной болезни
RU2478382C2 (ru) Комбинации вазоактивных веществ с эстрогенами и их применение для лечения сексуальных дисфункций у женщин
US20110015206A1 (en) Method of stabilizing lipid-rich plaque and method of preventing rupture thereof
KR20010041110A (ko) 트라마돌을 함유하는 약제학적 배합물
EA007952B1 (ru) Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии
JP2003528927A (ja) 腎機能障害の処置
US20250281481A1 (en) Naltrexone for boosting the therapeutic utilty of 5-ht receptor agonists
JP2015507006A (ja) ユリノキの樹皮のエキスを有効成分として含有する改善された医薬製剤
WO2003015700A2 (en) Novel vasoconstrictor cannabinoid analogs
CN102885821A (zh) 用于治疗胃肠道疾病的前列腺素衍生物
JP2006124296A (ja) ヘリコバクター・ピロリ菌感染症治療のための医薬組成物
EP1965800B1 (fr) Derives de piperidine pour leur utilisation dans le traitement des incontinences
US7842702B2 (en) Treatment for irritable bowel syndrome
JPH04279524A (ja) 脳血管疾患治療剤
EA003584B1 (ru) Способ стимуляции отказа от курения или его снижения или предупреждения возобновления курения и применение пароксетина или его фармацевтически приемлемых солей или сольватов для получения лекарственного средства
KR20240128504A (ko) 산 펌프 억제 활성을 갖는 신규 벤즈이미다졸 유도체
JPH0672876A (ja) 末梢血管抵抗改善による血圧降下剤
WO2005058326A1 (en) USE OF QUINAZOLINONE DERIVATIVES FOR THE INHIBITION OF TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS (TLESRs)
WO2015001358A1 (en) Drug combination and its use in therapy of obesity and type ii diabetes
HK1112679A (en) 5-[(2r)-[2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-2-methoxybenzenesulfonamide

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20081121